NASDAQ NMS - GLOBAL MARKET · DYN
+0.44% · +$0.0900 · Vol Not reported
Live · updated 05:54:44 ET
Dyne Therapeutics, Inc

Dyne Therapeutics, Inc

Biotechnology
$20.70
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is DYN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Dyne Therapeutics, Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
258
Country
US

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$20.61
Last session
Day high
$20.61
Last session
Day low
$20.61
Last session
Previous close
$20.61
52W high
$20.95
-1.19% from high
52W low
$17.67
92% of range
Market cap
$3.4B
EPS
$-3.5100
Shares out
165.3M
VWAP
$20.61
Last session
Price history computed in-house
1W
+4.55%
SMA 50 $19.32 · above
SMA 200 $19.32 · above
52W position 92%
Veridion warehouse edge

Warehouse intelligence for DYN.

Veridion Score
67
0: 671: 502: 563: 504: 805: 60
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

DYN insider activity

Dyne Therapeutics, Inc

Score
Coverage building
Pressure
Net selling
Filings
89
Buys / sells
8 / 81
Net value
-$60.9M
Insiders
7
Named filers
KD
Kersten Dirk
Insider
Leadership
PS
Posner Brian S
Insider
Leadership
FJ
Friedl-Naderer Johanna
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$60.9M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-242026-06-23Kersten DirkInsidersell$21.471,6573,848,256$36KSEC Form 4
2026-06-242026-06-23Kersten DirkInsidersell$21.0471,6293,849,913$1.5MSEC Form 4
2026-06-242026-06-22Kersten DirkInsidersell$20.57190,6763,921,542$3.9MSEC Form 4
2026-06-222026-06-18Kersten DirkInsidersell$20.0746,9014,112,218$941KSEC Form 4
2026-06-222026-06-17Kersten DirkInsidersell$20.1437,4544,159,119$754KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 84 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

DYN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DYN in this window.
Lobbying spend

DYN lobbying filings, year to date.

Registered lobbying filings matched to Dyne Therapeutics, Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DYN in this window.
Latest news · DYN
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for DYN.
Options
Sovereign unlock shows live options positioning for DYN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.